{"organizations": [], "uuid": "3e14512e1c5e9f61579c37e38b3909ef23095984", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abbvie-looking-to-return-additiona/brief-abbvie-looking-to-return-additional-cash-to-shareholders-idUSL1N1P5184", "country": "US", "domain_rank": 408, "title": "BRIEF-Abbvie Looking To Return Additional Cash To Shareholders", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-10T19:26:00.000+02:00", "replies_count": 0, "uuid": "3e14512e1c5e9f61579c37e38b3909ef23095984"}, "author": "", "url": "https://www.reuters.com/article/brief-abbvie-looking-to-return-additiona/brief-abbvie-looking-to-return-additional-cash-to-shareholders-idUSL1N1P5184", "ord_in_thread": 0, "title": "BRIEF-Abbvie Looking To Return Additional Cash To Shareholders", "locations": [], "entities": {"persons": [{"name": "bill berkrot", "sentiment": "none"}], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "upadacitinib immunology", "sentiment": "none"}, {"name": "abbvie inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 26 PM / Updated 28 minutes ago BRIEF-Abbvie Looking To Return Additional Cash To Shareholders Reuters Staff \nJan 10 (Reuters) - Abbvie Inc: \n* ABBVIE CEO SAYS ANTICIPATES REDUCTION IN TAX RATE AS RESULT OF US TAX REFORM \n* ABBVIE CEO PLANS TO MAKE SIGNIFICANT INVESTMENT IN US IN COMING YEARS WITH ACCESS TO OVERSEAS CASH \n* ABBVIE CEO SAYS PLANS TO ADVANCE NEUROSCIENCE PIPELINE TO CONTRIBUTE TO SALES GROWTH IN COMING DECADE \n* ABBVIE CEO SAYS RISANKIZUMAB FOR PSORIASIS AND RELATED INDICATIONS CAN BE $5 BILLION DRUG BY 2025 \n* ABBVIE CEO SAYS UPADACITINIB IMMUNOLOGY DRUG CAN REACH $6.5 BILLION SALES BY 2025 WITH SIX INDICATIONS \n* ABBVIE SAYS EXPECTS TO MOVE AT LEAST 10 DRUGS FOR SOLID TUMOR CANCERS TO CLINICAL TRIALS IN NEXT 12 MONTHS \n* ABBVIE CEO SAYS WILL LOOK FOR WAYS TO RETURN ADDITIONAL CASH TO SHAREHOLDERS Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)", "external_links": [], "published": "2018-01-10T19:26:00.000+02:00", "crawled": "2018-01-10T19:56:22.008+02:00", "highlightTitle": ""}